Randolph Company’s Meridian Bioscience Inc VIVO Stock Holding History

Randolph Company’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,510	Closed	-$418K	–	53
2021 Q4	$418K	Sell	20,510 -8,914	-30%	-$171K	0.05%	39
2021 Q3	$566K	Hold	29,424	–	–	0.07%	39
2021 Q2	$653K	Sell	29,424 -225	-0.8%	-$4.77K	0.08%	39
2021 Q1	$778K	Buy	+29,649	New	+$705K	0.11%	40
2017 Q1	–	Sell	-110,400	Closed	-$1.95M	–	42
2016 Q4	$1.95M	Hold	110,400	–	–	0.4%	36
2016 Q3	$2.13M	Buy	110,400 +3,200	+3%	+$62.6K	0.54%	28
2016 Q2	$2.09M	Hold	107,200	–	–	0.54%	25
2016 Q1	$2.21M	Hold	107,200	–	–	0.49%	30
2015 Q4	$2.2M	Sell	107,200 -550	-0.5%	-$10.5K	0.56%	27
2015 Q3	$1.84M	Buy	107,750 +9,900	+10%	+$181K	0.44%	32
2015 Q2	$1.82M	Hold	97,850	–	–	0.41%	32
2015 Q1	$1.87M	Buy	+97,850	New	+$1.81M	0.41%	30

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VLKIM

Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Randolph Company's VIVO Position: Q1 2022 in Review

Randolph Company sold out of Meridian Bioscience Inc (VIVO) in Q1 2022, closing a stake of 20,510 shares — an estimated $418K sold.

Randolph Company first reported a position in VIVO in Q1 2015 and held it in 12 quarters. The position peaked at $2.21M in Q1 2016. 210 funds tracked by Wall St. Rank hold VIVO as of Q1 2022.

Randolph Company reported no remaining Meridian Bioscience Inc position as of Q1 2022 after selling out during the quarter.
Randolph Company sold 20,510 Meridian Bioscience Inc shares in Q1 2022, an estimated $418K.
Randolph Company first reported a position in Meridian Bioscience Inc in Q1 2015 and held it in 12 quarters.
Randolph Company's Meridian Bioscience Inc position peaked at $2.21M in Q1 2016.
210 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2022.

Based on Randolph Company's 13F filing for Q1 2022, filed 29 Apr 2022.